Annual Accounts Receivable
$259.33 M
-$4.14 M-1.57%
December 31, 2023
Summary
- As of February 7, 2025, IART annual accounts receivable is $259.33 million, with the most recent change of -$4.14 million (-1.57%) on December 31, 2023.
- During the last 3 years, IART annual accounts receivable has risen by +$33.80 million (+14.98%).
- IART annual accounts receivable is now -5.80% below its all-time high of $275.30 million, reached on December 31, 2019.
Performance
IART Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$248.30 M
-$22.86 M-8.43%
September 30, 2024
Summary
- As of February 7, 2025, IART quarterly accounts receivable is $248.30 million, with the most recent change of -$22.86 million (-8.43%) on September 30, 2024.
- Over the past year, IART quarterly accounts receivable has dropped by -$7.97 million (-3.11%).
- IART quarterly accounts receivable is now -16.26% below its all-time high of $296.51 million, reached on June 30, 2019.
Performance
IART Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
IART Accounts Receivable Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -1.6% | -3.1% |
3 y3 years | +15.0% | -3.1% |
5 y5 years | -2.4% | -3.1% |
IART Accounts Receivable Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -1.6% | +11.9% | -8.4% | +7.1% |
5 y | 5-year | -5.8% | +15.0% | -9.8% | +38.6% |
alltime | all time | -5.8% | +1881.6% | -16.3% | +1863.3% |
Integra LifeSciences Holdings Accounts Receivable History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $248.30 M(-8.4%) |
Jun 2024 | - | $271.15 M(+12.5%) |
Mar 2024 | - | $241.09 M(-7.0%) |
Dec 2023 | $259.33 M(-1.6%) | $259.33 M(+1.2%) |
Sep 2023 | - | $256.27 M(-0.9%) |
Jun 2023 | - | $258.66 M(+1.8%) |
Mar 2023 | - | $254.00 M(-3.6%) |
Dec 2022 | $263.46 M(+13.6%) | $263.46 M(+6.1%) |
Sep 2022 | - | $248.27 M(+4.6%) |
Jun 2022 | - | $237.36 M(+1.4%) |
Mar 2022 | - | $234.01 M(+0.9%) |
Dec 2021 | $231.83 M(+2.8%) | $231.83 M(+4.3%) |
Sep 2021 | - | $222.23 M(-3.3%) |
Jun 2021 | - | $229.82 M(+2.8%) |
Mar 2021 | - | $223.54 M(-0.9%) |
Dec 2020 | $225.53 M(-18.1%) | $225.53 M(+3.4%) |
Sep 2020 | - | $218.18 M(+21.8%) |
Jun 2020 | - | $179.14 M(-27.0%) |
Mar 2020 | - | $245.55 M(-10.8%) |
Dec 2019 | $275.30 M(+3.6%) | $275.30 M(-2.1%) |
Sep 2019 | - | $281.12 M(-5.2%) |
Jun 2019 | - | $296.51 M(+6.2%) |
Mar 2019 | - | $279.07 M(+5.0%) |
Dec 2018 | $265.74 M(+5.5%) | $265.74 M(+6.8%) |
Sep 2018 | - | $248.74 M(-3.7%) |
Jun 2018 | - | $258.38 M(-5.1%) |
Mar 2018 | - | $272.26 M(+8.1%) |
Dec 2017 | $251.80 M(+69.9%) | $251.80 M(+47.1%) |
Sep 2017 | - | $171.13 M(-0.1%) |
Jun 2017 | - | $171.32 M(+8.3%) |
Mar 2017 | - | $158.23 M(+6.8%) |
Dec 2016 | $148.19 M(+12.1%) | $148.19 M(+5.3%) |
Sep 2016 | - | $140.75 M(-3.3%) |
Jun 2016 | - | $145.57 M(-4.0%) |
Mar 2016 | - | $151.61 M(+14.6%) |
Dec 2015 | $132.24 M(+19.8%) | $132.24 M(+5.4%) |
Sep 2015 | - | $125.47 M(-6.7%) |
Jun 2015 | - | $134.55 M(+6.1%) |
Mar 2015 | - | $126.78 M(+14.8%) |
Dec 2014 | $110.41 M(-6.5%) | $110.41 M(-8.6%) |
Sep 2014 | - | $120.74 M(+2.1%) |
Jun 2014 | - | $118.26 M(+5.1%) |
Mar 2014 | - | $112.52 M(-4.8%) |
Dec 2013 | $118.14 M(+2.8%) | $118.14 M(+4.1%) |
Sep 2013 | - | $113.54 M(-1.1%) |
Jun 2013 | - | $114.75 M(+2.5%) |
Mar 2013 | - | $111.94 M(-2.6%) |
Dec 2012 | $114.92 M | $114.92 M(-3.9%) |
Date | Annual | Quarterly |
---|---|---|
Sep 2012 | - | $119.53 M(+3.4%) |
Jun 2012 | - | $115.57 M(+1.4%) |
Mar 2012 | - | $114.00 M(-3.5%) |
Dec 2011 | $118.13 M(+11.4%) | $118.13 M(+0.3%) |
Sep 2011 | - | $117.78 M(+1.4%) |
Jun 2011 | - | $116.18 M(+9.5%) |
Mar 2011 | - | $106.12 M(+0.1%) |
Dec 2010 | $106.00 M(+2.7%) | $106.00 M(-1.1%) |
Sep 2010 | - | $107.15 M(+9.6%) |
Jun 2010 | - | $97.78 M(-0.8%) |
Mar 2010 | - | $98.53 M(-4.5%) |
Dec 2009 | $103.23 M(-8.2%) | $103.23 M(+1.8%) |
Sep 2009 | - | $101.38 M(-0.1%) |
Jun 2009 | - | $101.46 M(-0.1%) |
Mar 2009 | - | $101.61 M(-9.6%) |
Dec 2008 | $112.42 M(+8.6%) | $112.42 M(+1.2%) |
Sep 2008 | - | $111.08 M(+2.7%) |
Jun 2008 | - | $108.13 M(+1.2%) |
Mar 2008 | - | $106.88 M(+3.2%) |
Dec 2007 | $103.54 M(+21.8%) | $103.54 M(+12.2%) |
Sep 2007 | - | $92.31 M(-3.1%) |
Jun 2007 | - | $95.27 M(+10.9%) |
Mar 2007 | - | $85.88 M(+1.0%) |
Dec 2006 | $85.02 M(+73.5%) | $85.02 M(+10.8%) |
Sep 2006 | - | $76.72 M(+3.5%) |
Jun 2006 | - | $74.14 M(+31.0%) |
Mar 2006 | - | $56.61 M(+15.5%) |
Dec 2005 | $49.01 M(+4.8%) | $49.01 M(+4.7%) |
Sep 2005 | - | $46.79 M(+1.1%) |
Jun 2005 | - | $46.27 M(-9.7%) |
Mar 2005 | - | $51.26 M(+9.6%) |
Dec 2004 | $46.77 M(+61.6%) | $46.77 M(+23.0%) |
Sep 2004 | - | $38.03 M(+6.7%) |
Jun 2004 | - | $35.65 M(+17.6%) |
Mar 2004 | - | $30.32 M(+4.8%) |
Dec 2003 | $28.94 M(+49.1%) | $28.94 M(+7.3%) |
Sep 2003 | - | $26.96 M(+13.7%) |
Jun 2003 | - | $23.72 M(-1.4%) |
Mar 2003 | - | $24.07 M(+24.0%) |
Dec 2002 | $19.41 M(+38.4%) | $19.41 M(+9.5%) |
Sep 2002 | - | $17.72 M(+13.3%) |
Jun 2002 | - | $15.64 M(+5.5%) |
Mar 2002 | - | $14.83 M(+5.7%) |
Dec 2001 | $14.02 M(+7.2%) | $14.02 M(-3.0%) |
Sep 2001 | - | $14.45 M(-3.8%) |
Jun 2001 | - | $15.03 M(+18.9%) |
Mar 2001 | - | $12.65 M(-3.4%) |
Dec 2000 | $13.09 M | $13.09 M |
FAQ
- What is Integra LifeSciences Holdings annual accounts receivable?
- What is the all time high annual accounts receivable for Integra LifeSciences Holdings?
- What is Integra LifeSciences Holdings annual accounts receivable year-on-year change?
- What is Integra LifeSciences Holdings quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Integra LifeSciences Holdings?
- What is Integra LifeSciences Holdings quarterly accounts receivable year-on-year change?
What is Integra LifeSciences Holdings annual accounts receivable?
The current annual accounts receivable of IART is $259.33 M
What is the all time high annual accounts receivable for Integra LifeSciences Holdings?
Integra LifeSciences Holdings all-time high annual accounts receivable is $275.30 M
What is Integra LifeSciences Holdings annual accounts receivable year-on-year change?
Over the past year, IART annual accounts receivable has changed by -$4.14 M (-1.57%)
What is Integra LifeSciences Holdings quarterly accounts receivable?
The current quarterly accounts receivable of IART is $248.30 M
What is the all time high quarterly accounts receivable for Integra LifeSciences Holdings?
Integra LifeSciences Holdings all-time high quarterly accounts receivable is $296.51 M
What is Integra LifeSciences Holdings quarterly accounts receivable year-on-year change?
Over the past year, IART quarterly accounts receivable has changed by -$7.97 M (-3.11%)